Glaucoma Screening Using Artificial Intelligence Assisted Clinical Model in Singapore's Diabetic Eye Screening Program

Recruiting N/A Interventional Study
Glaucoma
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
21 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
1,040 (estimated)
Sponsor
Singapore Eye Research Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Glaucoma is major cause of irreversible blindness and is characterized by optic nerve damage and visual field loss. Screening for glaucoma is challenging due to lack of a simple, accurate, cost-efficient and standardized process. Artificial intelligence, (AI) especially deep learning (DL) algorithms have potential to automate glaucoma detection, but have to be evaluated in real world settings, bef…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: We aim to recruit all eligible patients who attend Singapore General Hospital (SGH) Diabetes \& Metabolism Centre's (DMC) clinics and SingHealth Polyclinics (SHP)-Bukit Merah under the Singapore Integrated Diabetic Retinopathy Programme (SiDRP). Patients are eligible for the stud…
Contacts

Ching-Yu Cheng, MD, PhD

65767277

chingyu.cheng@duke-nus.edu.sg

CONTACT

Lavanya Raghavan, MD

65767201

raghavan.lavanya@seri.com.sg

CONTACT